A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute Leukemia Study Group

Bekadja, Mohamed Amine; Hamladji, Rose Marie; Belhani, M; Ardjoun, Fatima Zohra; Abad, Mohand Tayeb; Touhami, Hadj; Ait-Ali, Hocine; Zouaoui, Zahia; Sidimansour, Noureddine; Hamdi, S.; Grifi, Fatiha; Mesli, Naima; Mh, Saidi; Mehalhal, N; Bachiri, A; Bouhass, R.; Said, Yousuf Mohamed; Midoun, N.

doi:10.5144/1658-3876.2011.161

Cited by 7 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median age of our patients was 46 years and the extreme range in age was from 18 years to 90 years. This age was similar to that reported by Bekadja et al in the Algerian population [31]. In contrast, this age was lower than that reported in many other studies, which prove the youthful character of the Moroccan AML patients [7-12-23-32-34].…”

Section: Discussionsupporting

confidence: 88%

Characteristics and Survival of 927 Moroccan Adults with Acute Myeloid Leukemia: Monocentric Experience

Boujmia

Lamchahab

Hda

et al. 2021

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

Acute myeloïd leukemia (AML) is the most frequent form of acute leukemia among adults and the most aggressive type of leukemia, which is associated with the lowest survival rate. Patients with AML are treated with intensive chemotherapy and many factors could influence the survival of these patients, such as age, cytogenetic abnormalities; white blood cell (WBC) counts. The aim of this work was to study the epidemiological and response profiles of AML adults patients in Morocco.Patients and Methods: A prospective, descriptive study conducted in the Hematology and Pediatric Oncology department, 20 August Hospital Casablanca, and concerned adult patients diagnosed with AML through a period of seven years (January 2011 to December 2017). Statistical analysis was performed using SPSS version 20. The overall survival and disease-free survival were evaluated by using the Kaplan–Meier method. Results: A total of 927 patients diagnosed with AML during the 7 year period. 466 (50.3%) were males and 461 (49.7%) were females. The median age of patients was 46years.The most represented age group was between 18 and 60 years old with a percentage of 83.2%.The FAB subtype M2 occurred most frequently (27%) followed by M1 (24.8%). The cytogenetic study showed that the majority of patients had a normal karyotype. The t (8; 21) was the most detected balanced translocation in our series and the intermediate cytogenetic group was the most represented group (65.4%). A total of 461 patients (53.54%) were treated according to the protocol AML11. The Disease-free survival (DFS) was significantly better for favorable cytogenetic group as compared to other cytogenetic groups (median survival of 41.58 months for the favorable group versus 29.07 months for the adverse group; p-value = 0.02).Conclusion: The age of AML patients was younger compared to other populations. The majority of patients had a normal karyotype and the commonest balanced translocation was the t (8; 21). Survival was higher in patients with good prognosis.

show abstract

Section: Discussionsupporting

confidence: 88%

Characteristics and Survival of 927 Moroccan Adults with Acute Myeloid Leukemia: Monocentric Experience

Boujmia

Lamchahab

Hda

et al. 2021

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

show abstract

“…Also, Abuhelwa et al in Palestine reported that AML-M4 was the most prevalent subtype in their study and AML-M7 was the least common subtype [10]. On the other hand, several studies reported that the most prevalent subtype was AML-M2 [13,[24][25][26][27][28]. Chang [12,29].…”

Section: Discussionmentioning

confidence: 99%

Cytogenetic profile of adult acute myeloid leukemia in Egypt: a single-center experience

et al. 2022

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) is a diverse disease characterized by the expansion of blasts of myeloid lineage. Cytogenetic testing is the cornerstone for risk stratification of AML patients. Geographical and environmental factors may play a very important role in the development of leukemia and several differences in genetic profile may be seen among different ethnicities. In our study, we evaluated cytogenetic findings of adult AML patients in South Egypt. Methods Cytogenetic testing (karyotyping and M-FISH) was performed for 120 adult patients with AML. Twenty metaphases were analyzed for each patient. Results In our study, the median age of AML patients was 36.5 years, with an age range between 18 and 86 years. 56.7% of patients had normal karyotypes and 43.3% of patients had clonal cytogenetic abnormalities. t (15;17) was the most detected structural abnormality, and + 8 was the most detected numerical abnormality. Regarding cytogenetic risk stratification, 65% of patients were in the intermediate-risk category. Conclusion The cytogenetic profile of AML patients in our locality showed some differences and some similarities with cytogenetic profiles in different Arab, Asian and Western countries. Further studies are needed using advanced techniques such as next-generation sequencing and optical genome mapping to elucidate more ethnic and geographic genetic heterogeneity among different countries.

show abstract

“…10,11 However, AML is more prevalent in patients younger than 60 years old in countries such as Brazil and Algeria. 12,13 In Saudi Arabia, the median age at diagnosis of AML appears to be lower than that reported for the United States and Europe, although the evidence base to support the assumption is limited to single institution experiences. 14,15 Although there is no published accurate estimate of AML ranking in comparison with other cancers, leukemia, in general, is a public health burden in Saudi Arabia and ranked as the fifth most prevalent type of cancer.…”

Section: Epidemiology and Burden Of Aml In Saudi Arabiamentioning

confidence: 99%

Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation

Alahmari

Alzahrani

Shehry

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE Acute myeloid leukemia (AML) is the most prevalent acute leukemia in adults and is responsible for the majority of cancer-related mortality. In Saudi Arabia, leukemia is ranked the fifth most prevalent type of malignancy in adults. Our aim is to review existing epidemiologic data in Saudi Arabia and develop consensus guidelines for management of AML. METHODS We review literature related to AML epidemiology, treatment patterns, and outcomes in Saudi Arabia, as well as literature related to the current advances in AML treatment. A panel of 10 experts from eight institutions in Saudi Arabia reviewed the literature and developed a consensus statement. RESULT We provide an update of the available AML epidemiologic data in Saudi Arabia and describe recent developments in the diagnostic workup, risk stratification, and treatment algorithm. The consensus recommendations for the management of AML in Saudi Arabia were developed. CONCLUSION The recommendations are in parallel with the recent international guidelines for the diagnosis and management of AML.

show abstract

A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute Leukemia Study Group

Cited by 7 publications

References 7 publications

Characteristics and Survival of 927 Moroccan Adults with Acute Myeloid Leukemia: Monocentric Experience

Characteristics and Survival of 927 Moroccan Adults with Acute Myeloid Leukemia: Monocentric Experience

Cytogenetic profile of adult acute myeloid leukemia in Egypt: a single-center experience

Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation

Contact Info

Product

Resources

About